You are here

Share:

News

Primary tabs

Virtual 2021 Technology Showcase - Thank you for attending

September 2, 2021

 Thank you for attending the virtual Technology Showcase on September 1. 

September 1, 2021 - Save the date

Wednesday, September 1, 2021
11:45 am - 5:15 pm  

See the full agenda here. Follow up with us here.

SPOTLIGHTED TECHNOLOGIES:

  • COVID19 mucosal vaccine studies in rhesus macaques
  • Single Domain Antibodies Targeting SARS-CoV-2 for treating COVID-19
  • Combination Therapy for Prostate and Breast Cancer
  • Antisense Oligonucleotides against Cancer Cell Migration and Invasion 
  • Efficacious Fluorinated Cytidine Analog Cancer Therapeutic with Low Toxicity in Animal Studies
  • The ARE-Del mouse: A novel model for autoimmunity
  • Polymeric Delivery Platform for Therapeutics
  • And more!

ADDITIONAL PANELS:

  • How to tap into the Frederick National Laboratory’s resources
  • Foundations and philanthropies as strategic partners
  • How to work with the National Cancer Institute and the Frederick National Laboratory
  • Government and for-profit funding and resources for startups

WHO SHOULD ATTEND?

  • Life-science / healthcare companies of all sizes
  • Investors, entrepreneurs
  • Technology scouts looking for technologies to commercialize
  • Economic development entities
  • Foundations
  • Interested stakeholders

EVENT OVERVIEW:

  • The 2021 Technology Showcase on September 1 will showcase technologies being developed at the NCI and the FNL to encourage startup company formation, technology licensing and collaborations 
  • Free, half-day virtual event
  • Hear from NCI and FNL inventors about technologies primed for collaboration and/or commercialization
  • Panel sessions focused on technology commercialization
  • Lightning Pitch and Poster session highlighting additional NCI technologies for collaborative development and/or /licensing presented by the NCI Technology Transfer Ambassadors Program

 

     

    Thank you! NCI Tech Opportunities Webinar: New HIV Vaccine to Treat and Prevent HIV

    July 14, 2021

    Thank you for attending the technology opportunity webinar on July 13, 2021.

    If you would like to learn more about this technology, including requesting a copy of the presentation, please reach out to reach out to Dr. Joseph Conrad, NCI TTC

    Attendees heard from the NCI’s Dr. Genoveffa Franchini about a new HIV vaccine with the potential to prevent HIV infection and treat HIV.  The effectiveness of the new vaccine results from deletion of the V1 region from gp120, enhancing the immune system’s ability to see and better target the virus’ gp120 V2 region. The NCI is seeking a collaboration partner for the NCI Phase 2 and 3 clinical trials for this vaccine and/or a licensing partner to bring the vaccine to market. Dr. Franchini will also discuss two other NCI technologies that further enhance the vaccine’s effectiveness:

    Why Attend?
    Who should attend?

    • Assess co-developing and/or licensing this technology
    • Interact with the inventor, ask questions and provide feedback
    • Learn how to partner with the NCI

    • Business development professionals
    • Drug development professionals
    • Biotech/pharma/academia researchers
    • Investors and entrepreneurs
      About the vaccine:

      This new vaccine’s effectiveness in macaques results from deletion of the V1 region from gp120, enhancing the immune system’s ability to see and better target the virus’ gp120 V2 region. The NCI is planning a Phase 1 clinical study on this vaccine at the NIH Clinical Center in late 2022.  

      What an HIV Vaccine could mean for patients - potential new standard of care

      Since 1985, the FDA approved 57 HIV therapeutics in seven HIV drug classes.  The current standard of care for treating HIV infection is a daily oral treatment with antiretroviral therapeutics, which are often combined with three other HIV medications selected from at least two different HIV drug classes. 

      An HIV vaccine would completely change the current way HIV infections are addressed.  For uninfected individuals, the HIV vaccine would protect them from contracting the disease. For infected individuals, it would substantially improve their quality of life by:

           • Providing a potential cure, rather than treating symptoms 
           • Eliminating the virus, rather than suppressing it
           • Providing a prime/boost treatment regimen for a finite amount of time, rather than lifelong daily dosing 

      Contact us if you are interested in learning more about this technology: ncitechtransfer@mail.nih.gov

      NCI Technology Opportunities Webinar: “Complete Tumor Regression Seen in Colon Cancer and Leukemia Animal Models with a Novel High Efficacy Fluorinated Cytidine Therapeutic Compound"

      May 8, 2021

      Thank you for attending this webinar on May 7th. If you were unable to attend and are interested in learning more about the featured technology, contact us for more information.

      OVERVIEW:

      The NCI TTC will host a webinar on May 7th to highlight NCI’s novel, therapeutic fluorinated cytidine compound that shows high efficacy against colon cancer and leukemia. Studies indicated that the therapeutic compound can produce complete regression in xenograph mouse models with minimal effects on body weight.  Registration is free.

      TECHNOLOGY DESCRIPTION

      • Potential therapeutic for various types of cancers – including colon cancer and leukemia
      • Comparative in vivo efficacy study in several human tumor xenograft studies indicated low toxicity and high efficacy vs. gemcitabine.
      • Produced complete tumor regression in colon cancer mouse models with a durable response beyond 150 days
      • Complete tumor regression was observed in a leukemia mouse xenograft model
      • Incorporating fluorine increases lipophilicity through steric and electronic effects.

      TECHNOLOGY COMPETITIVE ADVANTAGES

      • Oral activity
      • Increased lipophilicity blocks cancer cell metabolism and increases agent potency
      • Increased selectivity and decreased toxicity compared to other aza-cytidines

      Doctor Joel Morris, NCIPRESENTER:

      Joel Morris, Ph.D., Chief, Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, National Cancer Institute

      DATE & TIME: 

      May 26, 2021, 11:00am – Noon

      WHY ATTEND:

      • Assess the prospect of potentially licensing this technology.
      • Interact with the inventor, ask questions and provide feedback.
      • Learn how to partner with the NCI

      WHO SHOULD ATTEND:

      • Business development professionals
      • Drug development professionals
      • Biotech/pharma/academia Researchers
      • Investors
      • Entrepreneurs 

       

      Annual Technology Showcase Named Winner of 2021 Federal Laboratory Consortium (FLC) State and Local Economic Development Award

      February 3, 2021

      The FLC, a Congressionally mandated organization that educates, promotes, and facilitates federal technology transfer, announced its selection of NCI’s Annual Technology Showcase for its 2021 State and Local Economic Development Award. The FLC State and Local Economic Development Award recognizes successful initiatives that involve partnership between state or local economic development groups and federal laboratories for economic benefit.

      The Technology Showcase is an annual event created to provide scientists from NCI and the Frederick National Laboratory (FNL) a platform to highlight the commercial and life-saving potential of their discoveries to an audience of potential collaborators and licensees. It was conceived by the NCI Technology Transfer Center, the Frederick National Laboratory’s Partnership Development Office and the NCI Office of Scientific Operations. By hosting it at the FNL, they recognized the opportunity to partner with the economic development offices of the City and County of Frederick and the Technology Development Corporation of Maryland (TEDCO) to leverage their regional knowledge, resources, relationships, and expertise. The organizations agreed on goals and entered into a co-sponsorship agreement.

      The Technology Showcase – now going on its 5th year – centers around NCI and FNL researchers who made business pitches for their technologies to an audience of potential industry collaborators and licensees – in contrast to traditional presentations to a purely scientific audience. In addition, representatives from the NCI Technology Transfer Ambassadors Program – composed of post-doctoral scientists seeking unique professional/career education opportunities – develop and present posters highlighting the commercialization potential of additional NIH technologies. In 2020, the event organizers pivoted their efforts to deliver a virtual event that successfully provided interested parties an opportunity to participate regardless of location. The awareness and outreach provided by the annual Technology Showcase means that stakeholders understand they can turn to NCI and FNL when looking for a subject matter expert for collaboration to overcome a technology hurdle. Importantly, the effort serves to increase the likelihood that potentially life-saving cancer inventions may be developed and have a positive impact for patients.

      Award Recipients:
      NCI TTC:
      Michele Newton, Laura Prestia, Ph.D., Michael Salgaller, Ph.D. and Thomas Stackhouse, Ph.D.
      FNL:
      Victoria Brun, Maryellen Hackett, Vladimir Popov, Ph.D., Maggie Scully, Ph.D.
      NCI Frederick Office of Scientific Operations:
      Walter Hubert, Ph.D.
      Frederick County Department of Economic Development
      Heather Gramm, Helen Propheter
      Frederick City Department of Economic Development
      Mary Ford-Naill, Richard Griffin

      TTC-Hosted Technology Webinar Featured Novel Polymeric Drug Delivery Platform

      January 28, 2021

      TTC hosted a complimentary technology webinar on January 27 from 11:00 am - noon. Dr. Stephan T. Stern of the NCI Nanotechnology Laboratory located at the Frederick National Laboratory discussed his invention: "A Novel Lymphatic/Brain Targeting Macromolecular Prodrug System". 

      ABOUT THE TECHNOLOGY

      The invention is a novel polymeric drug delivery platform that targets the lymphatic system and brain through scavenger receptor A1 (SR-A1) mediated transcytosis. The SR-A1 receptor is highly expressed in macrophages, monocytes, mast cells, and dendritic cells (myeloid lineages), and also endothelial cells.
      This platform and lymphatic-targeting polymeric drug delivery system:

      • Can deliver various therapeutic/diagnostic imaging cargo to the brain, as well as to the lymphatic system and myeloid/antigen presenting cell (APC) sub-populations for treatment of various disease states or for tracking response to therapy.
      • Is particularly well suited for delivery of immunomodulatory drugs and delivering cancer therapeutics to the lymphatic environment that metastatic cancer cells use to spread to other parts of the body, including the brain.
      • Can enable prognostics for the lymphatic spread of metastatic cancers and evaluating treatment response

       If you are interested in learning more about this technology, please contact: Joseph.Conrad@nih.gov.

       
       

       

       

       

       

       

       

      Fellowship Opportunities at TTC

      December 3, 2020

      The TTC has fellowship opportunities available. A fellowship with TTC provides an opportunity for qualified candidates to apply a science, legal or business background to a career in technology transfer. Experience gained through the fellowship can create a new competency, preparing fellows for technology transfer positions within academia, industry, or the federal government. Learn more, including how to apply:  https://techtransfer.cancer.gov/aboutttc/jointtc

      2020 Technology Showcase Highlights NCI and FNL Technologies to Expanded Audience

      September 14, 2020

      The 2020 Technology Showcase welcomed more than 400 viewers to a half day event to encourage collaboration and licensing of inventions from the NCI and the Frederick National Laboratory (FNL). The pivot to a virtual format presented an opportunity to expand to a new audience. Attendees logged in from all over the world, including the United Kingdom, Switzerland, Brazil, Malaysia, and China.

      In addition to presentations by six NCI and three FNL inventors, the 2020 Technology Showcase included keynote presentations by Maryland Commerce Secretary, Kelly Schultz and Kite Pharma Senior Director Supply Chain, Howard Bland. There were also four educational panels given by moderators and panelists from investment firms, industry, nonprofits, and various government laboratories and agencies. In addition, representatives from the NCI Technology Transfer Ambassadors Program presented posters highlighting the commercialization potential of additional NIH technologies.

      In its fourth year, the Technology Showcase remains the only NCI event focused on attracting and informing industry licensees and partners. TTC’s Invention Development and Marketing Unit (IDMU) spearheads the planning of the annual event along with co-sponsors from the FNL, the Frederick County Office of Economic Development, the City of Frederick Department of Economic Development and TEDCO. Planning for a hybrid in-person / virtual event for 2021 is underway. A list of featured technologies, panel sessions and speakers featured can be found at: 2020 Technology Showcase .

      Licensing/Co-development Opportunity in T Cell Therapeutic for ALL

      July 24, 2020

      The National Cancer Institute seeks scientific and commercial development of an autologous CD22 CAR T-cell therapy for B-cell Acute Lymphoblastic Leukemia (ALL). A  Breakthrough Therapy Designation was received from the FDA based on observed responses in fifty-eight patients in a Phase I clinical trial sponsored by NCI. Details of the partnering arrangements can be reviewed on the NCI TTC web site. Statements of capability and interest from prospective parties interested in in-licensing or participating in co-development research should contact Jim Knabb, Ph.D., Senior Technology Transfer Manager, NCI TTC, knabbjr@nih.gov.

       

      2020 Technology Showcase to Go Virtual, September 9

      July 2, 2020

      The 4th Annual Technology Showcase is going virtual and will take place on September 9, 2020. The virtual event will feature a keynote address from Kite Pharma, panel sessions focused on technology commercialization and technology pitches from NCI and Frederick National Laboratory for Cancer Research scientists.  To learn more, visit 2020 Technology Showcase.

      NCI Wins Federal Laboratory Consortium Tech Transfer Awards

      February 19, 2020

      Two National Cancer Institute projects have been recognized with national awards from the Federal Laboratory Consortium for Technology Transfer (FLC). The winners will be recognized at the group’s National Meeting in Portland Oregon April 28-30. The FLC is a Congressionally mandated organization that educates, promotes, and facilitates federal technology transfer. Learn more about NCI’s awards below:

      Award 1: “New, First-in-class Immunotherapy, for Treatment of Recurrent, Metastatic Cervical Cancer”
      Winner of 2020 Excellence in Technology Transfer Award

      This award recognizes employees of FLC member laboratories and non-laboratory staff who have accomplished outstanding work in the process of transferring federally developed technology.

      Early in his career Steven Rosenberg, M.D., Ph.D., observed a patient with terminal cancer whose disease spontaneously disappeared and theorized it had something to do with the patient’s immune system. He and other researchers pursued this hypothesis for decades despite a skeptical scientific community. Today, Rosenberg’s pioneering research in cancer immunotherapy and individually designed “personalized” medicine is at the forefront of innovation, providing hope and cures for cancer patients who have exhausted all other treatments.

      In 2011, NCI and Iovance Biotherapeutics entered into a Cooperative Research and Development Agreement (CRADA) for the development of adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL). Technology licenses between NCI and Iovance were established to grant Iovance rights to the NIH’s TIL patent estate. Currently Iovance is conducting two pivotal multi-center trials of TIL technology in advanced cervical cancer and metastatic melanoma. In May 2019 the U.S. Food & Drug Administration (FDA) gave the technology a Breakthrough Therapy designation for advanced cervical cancer for patients who have exhausted all other treatment options. 

      Successes like the NCI-Iovance collaboration spur increases in medical research spending and investment. In June 2019, Iovance began construction of a 136,000 square foot TIL manufacturing plant in Philadelphia, Pennsylvania with capacity to meet demand for thousands of patients in multiple cancers. The next-generation facility aims to scale up TIL manufacturing and reduce the time and cost to produce the cells, which has been a major barrier for this type of treatment. The fact that immunotherapy treatments have the potential to provide cancer patients with improved quality of life with fewer, less severe side-effects will continue to attract investment and increase the development of new, lifesaving medical technologies.

      NCI, Iovance and its collaborators now have now initiated additional TIL trials in other solid tumors. This effective partnership has transferred an unprecedented immunotherapy treatment from a federal lab to the private sector advanced it to late-stage clinical development. The innovative treatment has the potential to help thousands of patients a year with deadly and previously untreatable forms of cancer.

      Winners:
      NCI Scientific Team
      Steven A. Rosenberg, M.D., Ph.D., chief, NCI Surgery Branch
      Christian Hinrichs, M.D., Investigator, NCI Experimental Transplantation and Immunotherapy Branch

      NCI TTC
      Aida Cremesti, Ph.D., Senior Technology Transfer Manager (TTM), NCI TTC
      Andrew Burke, Ph.D., TTM, NCI TTC

      Iovance Biotherapeutics
      Maria Fardis, Ph.D. MBA, CEO, Iovance

      Award 2: “NCI Technology Transfer Ambassadors Program: Innovative Internal and External Engagement”
      Winner of 2020 Technology Transfer Innovation Award

      This award recognizes federal laboratories that successfully implemented innovative or unconventional technology transfer approaches that resulted in a significant increase in technology transfer (T2) activities. This is a new FLC award category.

      In September 2016, to better engage and educate the scientific community, the NCI TTC launched the first federal Technology Transfer Ambassadors Program (TTAP). The program has significantly impacted technology transfer efforts across the NCI and is now being offered and adopted across the NIH.

      The TTAP is the first formal technology transfer training and mentoring program open to NIH post-doctoral scientists (post-docs) seeking professional development in invention analysis, commercialization, and entrepreneurship. The one-year program augments each post-doc’s current research activities and boosts the impact on the technology transfer environment at NIH.

      While TTAP has received positive feedback and results since first implemented in 2016, TTAP’s strength directly stems from efforts to continuously enhance the program. In 2019, program leads included a new “Technology Transfer Boot Camp,” a series of intensive hands-on training sessions to equip post-doc participants with skills immediately applicable to their training while they worked directly with TTC managers. Additionally, the leads developed a “Perfecting Your Pitch” workshop and “Pitch Practice” sessions for post-doc participants to learn how to effectively communicate the value propositions of technologies to business audiences. Since participating in TTAP, several post-doc participants have transitioned their careers into technology transfer and many other related professions.

      TTAP has and continues to strive toward creating a lab-to-market mindset across NIH Institutes.  In some labs, a paradigm shift has investigators focusing research efforts on outcomes with more of an eye to commercialization. The result is a more entrepreneurial culture, stronger connections between technology transfer and the scientific community, and enhanced efficiency of NIH technology transfer efforts for commercialization.

      Successful outcomes include multiple invention disclosures and transactional agreements initiated by post-doc participants, dozens of analyses and presentations informing NIH patent investment decisions, improved marketing campaigns for NIH technologies, and an increase in creative TT engagement with scientists.

      Winners: Technology Transfer Ambassador Team Leads, NCI TTC:
      Laura Prestia, Ph.D., Communications & Strategic Initiatives Manager
      Rose Freel Ph.D., Senior Technology Transfer Manager (TTM)
      Taryn Dick Ph.D., M.B.A., TTM
      Abritee Dhal Ph.D., TTM

      More information about TTAP can be found at: https://techtransfer.cancer.gov/aboutttc/ambassadors

      Pages